DE60038951D1 - Verfahren zur inhibierung von gehirntumorwachstum durch verwendung von antagonisten von integrinen - Google Patents

Verfahren zur inhibierung von gehirntumorwachstum durch verwendung von antagonisten von integrinen

Info

Publication number
DE60038951D1
DE60038951D1 DE60038951T DE60038951T DE60038951D1 DE 60038951 D1 DE60038951 D1 DE 60038951D1 DE 60038951 T DE60038951 T DE 60038951T DE 60038951 T DE60038951 T DE 60038951T DE 60038951 D1 DE60038951 D1 DE 60038951D1
Authority
DE
Germany
Prior art keywords
antagonists
brain tumor
integrins
tumor growth
inhibiting brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60038951T
Other languages
English (en)
Inventor
Walter E Laug
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital Los Angeles
Original Assignee
Childrens Hospital Los Angeles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26815994&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60038951(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Childrens Hospital Los Angeles filed Critical Childrens Hospital Los Angeles
Application granted granted Critical
Publication of DE60038951D1 publication Critical patent/DE60038951D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
DE60038951T 1999-02-01 2000-01-26 Verfahren zur inhibierung von gehirntumorwachstum durch verwendung von antagonisten von integrinen Expired - Lifetime DE60038951D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11812699P 1999-02-01 1999-02-01
US09/489,391 US6521593B1 (en) 1999-02-01 2000-01-21 Methods for inhibiting brain tumor growth
PCT/US2000/001949 WO2000044404A2 (en) 1999-02-01 2000-01-26 Methods for inhibiting brain tumor growth by using selected integrin antagonists

Publications (1)

Publication Number Publication Date
DE60038951D1 true DE60038951D1 (de) 2008-07-03

Family

ID=26815994

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60038951T Expired - Lifetime DE60038951D1 (de) 1999-02-01 2000-01-26 Verfahren zur inhibierung von gehirntumorwachstum durch verwendung von antagonisten von integrinen

Country Status (21)

Country Link
US (2) US6521593B1 (de)
EP (1) EP1150714B1 (de)
JP (1) JP4708568B2 (de)
KR (1) KR100704139B1 (de)
CN (2) CN1191858C (de)
AT (1) ATE395934T1 (de)
AU (2) AU775064B2 (de)
BR (1) BR0007875A (de)
CA (1) CA2360146C (de)
CZ (1) CZ301480B6 (de)
DE (1) DE60038951D1 (de)
DK (1) DK1150714T3 (de)
ES (1) ES2304942T3 (de)
HU (1) HU230025B1 (de)
MX (1) MXPA01007765A (de)
NO (1) NO329695B1 (de)
PL (1) PL202082B1 (de)
PT (1) PT1150714E (de)
RU (1) RU2377017C2 (de)
SK (1) SK287326B6 (de)
WO (1) WO2000044404A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60042731D1 (de) * 1999-01-06 2009-09-24 Univ Southern California Methode und zubereitung zur hemmung von angiogenese
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
JP4351043B2 (ja) * 2001-07-09 2009-10-28 エラン ファーマシューティカルズ，インコーポレイテッド アミロイド毒性の阻害方法
US7829087B2 (en) 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
WO2005044978A2 (en) * 2003-07-15 2005-05-19 Washington University Methods of treating, preventing and inhibiting cancer metastasis and tumor formation
EP2335694B1 (de) 2003-09-15 2018-06-13 NanoPharmaceuticals LLC Thyroidhormon-analoga und deren verwendung
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
ITRM20040105A1 (it) * 2004-02-27 2004-05-27 Tecnogen Scpa Anticorpo monoclonale antitenascina umana.
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US20090022806A1 (en) * 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
WO2007035612A2 (en) 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
CA2622852A1 (en) * 2005-09-30 2007-04-12 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
EP2054442A2 (de) * 2006-06-14 2009-05-06 Cell-Matrix, Inc. Denaturierte collagen-peptide und anwendungen davon
AU2007348941B2 (en) 2006-08-03 2011-08-04 Medimmune Limited Antibodies directed to alphaVbeta6 and uses thereof
EP2120913B1 (de) * 2006-12-22 2015-01-21 NanoPharmaceuticals LLC Nanopartikel- und polymerformulierungen für schilddrüsenhormonanaloga, -antagonisten und -formulierungen sowie verwendungen damit
EP2192919A1 (de) * 2007-08-24 2010-06-09 University Health Network Verfahren zur hemmung des tumorwachstums mit beta-5-integrin-antagonisten
JP5680547B2 (ja) 2008-12-23 2015-03-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 抗血管形成活性を有するインヒビターのためのバイオマーカー
US20100159021A1 (en) * 2008-12-23 2010-06-24 Paul Davis Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use
US9180107B2 (en) * 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
CN101659694B (zh) * 2009-05-06 2012-12-12 河北科技大学 抗肿瘤环五肽化合物及其制备方法
CA2765792C (en) * 2009-06-17 2017-03-28 Ordway Research Institute, Inc. Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US9554988B2 (en) 2010-06-30 2017-01-31 Galderma Research & Development Method for preventing or treating skin tumor
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
CN102145161A (zh) * 2011-04-07 2011-08-10 中国药科大学 整合素阻断剂在制备治疗肿瘤药物中的应用
JP6426001B2 (ja) 2011-11-17 2018-11-21 グリア エスピー ゼット．オー．オー． 神経膠腫を治療するための組成物および方法
CN102417540A (zh) * 2011-11-21 2012-04-18 中国药科大学 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
US20170000905A1 (en) * 2015-06-30 2017-01-05 Mousera, Inc Device and method of personalized medicine
WO2017214299A1 (en) 2016-06-07 2017-12-14 Nanopharmaceuticals, Llc NON-CLEAVABLE POLYMER CONJUGATED WITH αvβ3 INTEGRIN THYROID ANTAGONISTS
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
WO2020030954A1 (en) 2018-08-09 2020-02-13 Integrative Medicine Clinic, Sia Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer
RU2709215C1 (ru) * 2019-09-12 2019-12-17 Федеральное государственное бюджетное учреждение науки "Федеральный исследовательский центр "Институт катализа им. Г.К. Борескова Сибирского отделения Российской академии наук" (ИК СО РАН) Способ подавления роста опухолей глиального происхождения
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
ES2202336T3 (es) * 1994-12-20 2004-04-01 Merck Patent Gmbh Anticuerpo monoclonal contra la integrina alfa-v.
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE19613933A1 (de) * 1996-04-06 1997-10-09 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
JP2002515036A (ja) * 1996-05-31 2002-05-21 ザ スクリップス リサーチ インスティテュート α▲下Ｖ▼β▲下５▼媒介血管形成の抑制に有用な方法および組成物
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
CZ20002269A3 (cs) * 1998-12-14 2001-01-17 Merck & Co., Inc. Látky antagonizující receptor íntegrinu

Also Published As

Publication number Publication date
BR0007875A (pt) 2002-02-13
NO20013750L (no) 2001-09-28
PT1150714E (pt) 2008-07-30
CN1355711A (zh) 2002-06-26
JP2002535375A (ja) 2002-10-22
HUP0105155A2 (hu) 2002-04-29
ES2304942T3 (es) 2008-11-01
KR100704139B1 (ko) 2007-04-09
CZ20012793A3 (cs) 2002-03-13
NO20013750D0 (no) 2001-07-31
ATE395934T1 (de) 2008-06-15
CA2360146A1 (en) 2000-08-03
CA2360146C (en) 2013-05-21
SK287326B6 (sk) 2010-07-07
US6521593B1 (en) 2003-02-18
DK1150714T3 (da) 2008-08-18
RU2377017C2 (ru) 2009-12-27
AU775064B2 (en) 2004-07-15
WO2000044404A2 (en) 2000-08-03
PL202082B1 (pl) 2009-05-29
CN1191858C (zh) 2005-03-09
EP1150714B1 (de) 2008-05-21
MXPA01007765A (es) 2003-06-04
SK10622001A3 (sk) 2002-04-04
HUP0105155A3 (en) 2004-08-30
CZ301480B6 (cs) 2010-03-17
AU2737900A (en) 2000-08-18
PL359602A1 (en) 2004-08-23
CN1332713C (zh) 2007-08-22
CN1660426A (zh) 2005-08-31
JP4708568B2 (ja) 2011-06-22
US20030157098A1 (en) 2003-08-21
RU2005107614A (ru) 2006-08-27
EP1150714A2 (de) 2001-11-07
AU2004220756A1 (en) 2004-11-11
WO2000044404A3 (en) 2000-11-30
NO329695B1 (no) 2010-12-06
AU2004220756B2 (en) 2007-05-10
KR20020001726A (ko) 2002-01-09
HU230025B1 (hu) 2015-05-28

Similar Documents

Publication Publication Date Title
DE60038951D1 (de) Verfahren zur inhibierung von gehirntumorwachstum durch verwendung von antagonisten von integrinen
AU4721901A (en) Integrin antagonists
ATE253903T1 (de) Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor
ATE418999T1 (de) Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung
ATE401909T1 (de) Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
ATE494388T1 (de) Neues verfahren zum erschaffen von proteinkinase- inhibitoren
ATE374642T1 (de) Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose
ATE511861T1 (de) Verfahren zur inaktivierung von mikroorganismen unter verwendung von photosensibilisatoren
ATE288197T1 (de) Verfahren zur kryokonservierung von samenzellen
DE69810351D1 (de) Verfahren zur begrenzung des wachstums von mikroorganismen durch verwendung metallhaltiger verbindungen
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
ATE306932T1 (de) Modulierung von gedächtnis-effector t-zellen unter verwendung eines cd2-bindungsagentes
GB2393735B (en) Cell culture method for obtaining prostate-like acini
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
DE60042793D1 (de) Inhibitor des hepatozytwachstumsfaktoraktivators und dessen verwendung zur modulation von angiogenese und herzvaskularisierung
DE1206274T1 (de) Verwendung von interleukin-18-inhibitoren zur hemmung von tumormetastasierung
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
DE60011785D1 (de) Verfahren zur herstellung von proteinen in wirtszellen unter verwendung von chaperoninen
DE69932342D1 (de) Verfahren und zusammensetzungen zur hemmung von neoplastischem zellwachstums
DE59910945D1 (de) Hemmung von alopezie
DE60328979D1 (de) Androgen-reguliertes pmepa1 gen und verfahren zu seiner verwendung zur hemmung von krebszellwachstum
ATE383575T1 (de) Verfahren zur herstellung einer normalisierten genbank aus nukleinsäure-exktrakten von bodenproben und deren verwendung
ATE225660T1 (de) Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz
DE602004018121D1 (de) Verwendung von alpha2-adrenorezeptor antagonisten zur behandlung von epilepsie

Legal Events

Date Code Title Description
8363 Opposition against the patent